M
Matthew J. Stiller
Researcher at Harvard University
Publications - 52
Citations - 2630
Matthew J. Stiller is an academic researcher from Harvard University. The author has contributed to research in topics: Randomized controlled trial & Terbinafine. The author has an hindex of 25, co-authored 52 publications receiving 2478 citations. Previous affiliations of Matthew J. Stiller include New York University.
Papers
More filters
Journal ArticleDOI
A comparison of current acne grading systems and proposal of a novel system
TL;DR: Until a more reliable quantitative psychometric instrument is developed, the psychosocial impact of acne must be documented elsewhere in the patient's record.
Journal ArticleDOI
Dapsone and sulfones in dermatology: overview and update.
Y. Isabel Zhu,Matthew J. Stiller +1 more
TL;DR: The chemistry, pharmacokinetics, clinical application, mechanism of action, adverse effects, and drug interactions of dapsone and the sulfones in dermatology are reviewed and updated.
Journal ArticleDOI
Tretinoin emollient cream: A new therapy for photodamaged skin
Elise A. Olsen,H. Irving Katz,Norman Levine,Jerome L. Shupack,Meda McCarley Billys,Steven E. Prawer,Jonathan A. Gold,Matthew J. Stiller,Laura Lufrano,E. George Thome +9 more
TL;DR: Mild to moderate skin reactions were the most common side effects and, although most prevalent in the group using the 0.05% concentration, generally did not limit tretinoin use.
Journal ArticleDOI
Topical 8% glycolic acid and 8% L-lactic acid creams for the treatment of photodamaged skin. A double-blind vehicle-controlled clinical trial.
Matthew J. Stiller,John Bartolone,Robert S. Stern,Shondra L. Smith,Nikiforos Kollias,Robert Gillies,Lynn A. Drake +6 more
TL;DR: Topical 8% glycolic acid and 8% L-lactic acid creams are modestly useful in ameliorating some of the signs of chronic cutaneous photodamage and are well tolerated and available without prescription.
Journal ArticleDOI
Effect of onychomycosis on quality of life
Lynn A. Drake,Richard K. Scher,Edgar B. Smith,Gerald A. Faich,Shondra L. Smith,Joseph J. Hong,Matthew J. Stiller +6 more
TL;DR: Relevance of quality-of-life issues to overall health, earning potential, and social functioning should prompt reconsideration of the value of aggressive treatment of and financial coverage for onychomycosis.